Zai Lab (MEX:ZLAB N) 1-Year Sharpe Ratio: -105.91 (As of Jul. 09, 2026)


MEX:ZLAB N Zai Lab Ltd MEX:ZLAB N
64 GF Score
Price MXN810.00
GF Value MXN1,240.85
! 7 Warning Signs
View Full Analysis

What is Zai Lab 1-Year Sharpe Ratio?

Zai Lab MEX:ZLAB N 64 1-Year Sharpe Ratio is -105.91 as of Jul. 09, 2026. GuruFocus rates MEX:ZLAB N with a GF Score™ of 64/100 and a GF Value™ of MXN1,240.85. The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-09), Zai Lab's 1-Year Sharpe Ratio is -105.91.

Zai Lab  (MEX:ZLAB N) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Zai Lab 1-Year Sharpe Ratio Related Terms

MEX:ZLAB N vs STOK, ADMA, VRDN: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Zai Lab's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zai Lab 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Zai Lab's 1-Year Sharpe Ratio falls into.


MEX:ZLAB N
64GF Score
Zai Lab Ltd MEX:ZLAB N
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -105.91 mean?
Zai Lab (MEX:ZLAB N) has a 1-Year Sharpe Ratio of -105.91 as of Jul. 09, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Zai Lab and its competitors.
Is Zai Lab's 1-Year Sharpe Ratio too high?
Zai Lab's current 1-Year Sharpe Ratio is -105.91. Overall, Zai Lab has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 1-Year Sharpe Ratio compare to STOK and ADMA?
Zai Lab's 1-Year Sharpe Ratio of -105.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Zai Lab and its competitors. Zai Lab's current 1-Year Sharpe Ratio is -105.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Zai Lab (MEX:ZLAB N) has a current 1-Year Sharpe Ratio of -105.91. The stock's GF Value™ is MXN1,240.85, compared to a current price of MXN810.00 — trading 34.7% below its estimated fair value. The current 1-Year Sharpe Ratio is -105.91. Zai Lab's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Zai Lab (MEX:ZLAB N), the current 1-Year Sharpe Ratio is -105.91 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (MEX:ZLAB N) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of MXN810.00 is trading 34.7% below its estimated GF Value™ of MXN1,240.85.

Key valuation signals for MEX:ZLAB N:

  • 1-Year Sharpe Ratio: -105.91
  • GF Value™: MXN1,240.85 vs. price of MXN810.00 (34.7% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the MEX:ZLAB N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for MEX:ZLAB N

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN1,240.85
GF Value